• Travere Therapeutics disclosed that Chief Accounting Officer Sandra Calvin will retire following the filing of its annual report expected in February 2027.
• Vice President, Controller John Torell is expected to succeed Calvin as chief accounting officer and principal accounting officer, with an appointment planned ahead of the transition.
• Torell has led accounting operations, financial reporting, SEC reporting, technical accounting, internal controls; joined in 2021, has served as VP, Controller since 2023.
• He previously held senior finance roles at Pacific Life Insurance Company from 1997 to 2019, including Vice President, Controller; earlier worked as an audit manager at Deloitte.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Travere Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001438533-26-000054), on July 09, 2026, and is solely responsible for the information contained therein.